TSE:JWEL

Jamieson Wellness (JWEL.TO)

41.93
+0.19 (0.46%)
as of Jul 15, 2026, 8:00:00 pm Market Open.
152 watching
0
Investor Insights
star iconJul 16, 2026, 12:00 am

This summary was created by AI, based on 2 opinions in the last 12 months.

Jamieson Wellness (JWEL-T) has garnered positive reviews from analysts who highlight its strong core business performance and the potential for future unsolicited takeout offers. With a solid growth trajectory, having expanded its operations into China and acquired a California company, Jamieson is well-positioned in the nutraceutical market, especially given the minimal impact from tariffs. The company has been able to consistently grow its dividend at a rate of 14% over the past five years, providing an appealing yield of 2.55%. Analysts suggest that despite the recent appreciation in stock price, the likelihood of a takeout is greater than market expectations, making it an attractive buy at this point. Overall, the sentiment from experts reflects confidence in the company's strategic direction and financial health.

consensus icon
Consensus
Buy
valuation icon
Valuation
Undervalued
review icon
Similar
Herbalife,HLF

Most recent Opinions go here

Be up to date, don't miss your chance.

BUY

Unsolicited takeout offer. Core business doing quite well. He'd buy, despite recent stock appreciation, as odds of a takeout are higher than the market is expecting.

TOP PICK

To "pump up" portfolios across Canada. Founded in Windsor ON. Bought a California company a few years ago, so little to no impact from tariffs. Growing in China, where company's attention to quality makes it stand apart. Seeing takeouts of private vitamin/mineral companies at much higher valuations. Has grown dividend over last 5 years at 14% clip. Yield is 2.55%.

(Analysts’ price target is $42.43)
BUY

Bottomed back in 2023. Since then a defined uptrend, with higher highs and higher lows. Chart looks good, stock remains in a trading range. Next upside target is ~$40.50.

WATCH

Good business, decent ROIC. Multiple's not inexpensive. Lots of retailers are available under 13x with great ROIC. He continues to meet with management.

HOLD
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research

There has been no signficant recent company news, good or bad. It recently did get some upgrades, with TD noting 'strong contributions from the Chinese market, and no negative operational news'. The decline could be general small cap aversion or tariff fears, as we cannot point to anything specific here. The last quarter was mixed, but estimates have slowly ticked up over the last month. We would consider it OK, with high debt the main drawback for us. 
Unlock Premium - Try 5i Free

TOP PICK

Huge margins and free cashflow. Growing business annually compounded at over 15%. International expansion. US acquisition is growing double digits. Online China business growing 80%. Never been cheaper at 17x forward PE. Takeover potential in a few years. Yield is 2%.

(Analysts’ price target is $40.82)
HOLD

He owns it and likes it even though the price movement has been disappointing. It is consolidating here. Analysts have a $38 to$42 price target.

DON'T BUY
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research

EPS of 9c beat estimates of 6c; revenue of $128M beat estimates of $123.1M. EBITDA of $16M matched estimates. Year forecast was maintained. A couple of brokers lowered targets. Revenue fell 6.4% with a large decline in Strategic Partners business with the closing of a contract. Gross margins declined. While this was a 'beat' versus expectations, debt remains too high for our comfortable level, considering the fairly big decline in growth vs prior year. We think buyers can wait.
Unlock Premium - Try 5i Free

BUY
Adding to small- and mid-caps?

That's right. They've been severely beaten up over the last few years. Massive outflow of funds out of Canada, and it hits the smaller stocks even more. A lot of retail investors put in fund redemptions last year, so that created many bargains.

Over the last 6 months, he added to many of his small- and mid-cap positions. Companies like QTRH, JWEL, and EQB.

TOP PICK

Canada's #1 brand in its sector, has 25% market share. Went public 6-7 years ago, and increased sales and profits every year. US acquisition should accelerate growth. Now controls direct distribution in China. Cheaper than ever at 18x earnings, but growth prospects are better than ever. High margin, high quality, steady. Great entry point. Yield is 2.32%.

(Analysts’ price target is $43.53)
DON'T BUY

He sold it after a recent disappointing earnings report (lowered their guidance a lot). After all, they're not in a cyclical business. Their acquisition of a Chinese company was interesting, though the structure was unusual--they bought $100 million in preferred shares with warrants but no dividend and took a minority share in the Chinese business. That was the right move in the Chinese market. Otherwise, JWEL's fundamentals didn't impress him. The stock isn't getting much love these days.

PAST TOP PICK
(A Top Pick Jun 06/22, Down 20%)

Sold off, as investors assumed a pandemic bump. Sales continue to grow organically. Continues to gain market share. US acquisition lets them accelerate growth. Expanding dramatically in China. 19x earnings. Very high quality company.

BUY
Going forward, will be a large market for healthcare products. Aging population will ensure demand for products. Vitamins will help aging population. Healthcare will do well in the long term.
BUY
It's pulled back from its Covid highs, but there is a steady demand for vitamins. Pays a small dividend. There is upside potential when the market turns up, but steady during tough times.
BUY
Allan Tong’s Discover Picks Vitamins are defensive, something you need in today’s uncertain markets where the street keeps chattering about recession. The street likes JWEL stocks with seven buys and no holds or sells and expects about 30% upside at a $45.64 price target. JWEL stocks are still a ways off their $41.70 52-week high. Read Our 3 defensive healthcare stocks picks for our full analysis.
Showing 1 to 15 of 35 entries

Jamieson Wellness (JWEL.TO) Frequently Asked Questions

What is Jamieson Wellness stock symbol?

Jamieson Wellness is a Canadian stock, trading under the symbol JWEL.TO (previously JWEL-T on Stockchase) on the Toronto Stock Exchange (JWEL-CT). It is usually referred to as TSX:JWEL or JWEL.TO

Is Jamieson Wellness a buy or a sell?

In the last year, 2 stock analysts issued a Buy, Sell, or Hold rating on JWEL.TO (previously JWEL-T on Stockchase). 2 analysts recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is BUY. Read the latest stock experts' ratings for Jamieson Wellness.

Is Jamieson Wellness a good investment or a top pick?

Jamieson Wellness was recommended as a Top Pick by Andrey Omelchak on 2026-06-26. Read the latest stock experts ratings for Jamieson Wellness.

Why is Jamieson Wellness stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Jamieson Wellness.

Is Jamieson Wellness worth watching?

Jamieson Wellness is followed by 152 investors on Stockchase and is a trending stock that is worth watching.

What is Jamieson Wellness stock price?

On 2026-07-15, Jamieson Wellness (JWEL.TO) stock closed at a price of $41.93.